Although the covid pandemic mitigations have been challenging, they have resulted in a perspective adjustment at MSACL that has revealed an exciting opportunity to extend the
knowledge base of the MSACL community even further into the research and clinical space ... consistent online content.
Under this new paradigm of operation, we are offering a platform of engagement to provide not only classical SCIENTIFIC CONTENT, but also to extend
the best of the MSACL NETWORKING effects -- such as those found during Booth and Poster Tours, and the Meet-a-Mentor program -- into the virtual space. SHORT COURSES are also a part of the Connect ecosystem.
Tue
Jun
11, 2024
Los Angeles : 07:00 AM - 08:00 AM
NEW YORK:
Jun 11 • 10:00 AM - 11:00 AM
LONDON:
Jun 11 • 03:00 PM - 04:00 PM
PARIS:
Jun 11 • 04:00 PM - 05:00 PM
INDIA:
Jun 11 • 07:30 PM - 08:30 PM
CHINA:
Jun 11 • 10:00 PM - 11:00 PM
SYDNEY:
Jun 12 • 12:00 AM - 01:00 AM
Industry Solutions
There is no cost to register for this activity.
Clinical metabolomics use cases to improve diagnosis and monitoring of endocrine disorders
Antonin Lamazière
Sorbonne Université
Antonin Lamazière is a professor and hospital practitioner at Sorbonne University's Faculty of Medicine. He heads the Hospital Department of Clinical Metabolomics at Hôpital Saint Antoine (AP-HP.Sorbonne Université).
His research interests lie at the interface between metabolism, nutrition and endocrine and metabolic pathologies. Through his work, he proposes translational approaches based on more fundamental pathophysiological issues, leading to the development of new diagnostic tools for use in healthcare. Recently, he and his team have highlighted the benefits of combining targeted metabolomic approaches with mathematical modeling based on machine learning and AI. The aims are both to map and better understand certain major biochemical pathways, and to envisage new endocrine semiologies to improve patient management and therapeutic follow-up.
With the performance of new devices, mass spectrometry now offers real opportunities in terms of diagnosis and therapeutic follow-up, particularly in the neuro-endocrine field. Through examples of routine clinical developments carried out in our clinical department, this presentation will show how gains in sensitivity and robustness enable us to access new endocrine semiologies with simultaneous assays of endogenous/exogenous steroid profiles in serum or on DBS, assays of somatotropic axis peptides or the use of mathematical models to develop digital medical devices.
This webinar will cover the following:
• Circulating steroid profiling improves management of PCOS syndrome
• Clinical applications of metabolomics DBS signatures
• High sensitivity 7500Qtrap enhances performances of proteomic biomarkers quantitation
https://www.msacl.org?header=Connect#348
1
Thu
Jun
20, 2024
Los Angeles : 09:00 AM - 10:00 AM
NEW YORK:
Jun 20 • 12:00 PM - 01:00 PM
LONDON:
Jun 20 • 05:00 PM - 06:00 PM
PARIS:
Jun 20 • 06:00 PM - 07:00 PM
INDIA:
Jun 20 • 09:30 PM - 10:30 PM
CHINA:
Jun 21 • 12:00 AM - 01:00 AM
SYDNEY:
Jun 21 • 02:00 AM - 03:00 AM
Seminar
There is no cost to register for this activity.
Moderator(s):
Mari DeMarco, PhD, DABCC, FACB, FCACB University of British Columbia
Can pre-clinical proteomics support therapy selection in precision medicine? A proof of
concept.
Philipp Lange, PhD
BC Children's Hospital, University of British Columbia
Dr. Philipp Lange is Canada Research Chair in Translational Proteogenomics of Pediatric Malignancies and Associate Professor of Pathology at the University of British Columbia (UBC). He is also a Scientist in the Michael Cuccione Childhood Cancer Research Program at the BC Children’s Hospital and the BC Cancer Research Institute.
Dr. Lange’s research focuses on precision oncology and oncoproteoforms, proteins with cancer-specific post-translational modification, their altered function, role in cell-cell communication and drug resistance, and their potential use as drug targets and biomarkers. His team drives the development and translation of proteomics platforms to advance molecular pathology and guide precision treatment for kids with cancer.
Dr. Lange provides leadership for Cancer Biology in the Canadian Pediatric Cancer Consortium ACCESS and co-leads the multi-centre proteomics team in the Canadian Precision Oncology For Young People (PROFYLE) study. He has won several awards for his advances in cancer research including the CIHR Early Career Investigator in Cancer Award and the Great Canadian Innovation Award by the Canadian Cancer Society.
Dr. Philipp Lange received his PhD in Biochemistry from the Free University Berlin, Germany after earning an MSc in Molecular Biology, Microbiology and Computer Sciences from the University of Hamburg, Germany. During his PhD with Dr. Dr. Thomas Jentsch at the Max Delbruck Centre for Molecular Medicine, Berlin, Germany he studied the molecular causes of hereditary osteopetrosis in children and patented a new drug target for the treatment of osteoporosis in adults. He conducted his postdoctoral work with Dr. Christopher Overall at the Centre for Blood Research, UBC developing computational and proteomics approaches to study post-translational modification in cancer.
Molecularly targeted precision treatments have significant potential to improve therapy options for hard-to-treat cancers and reduce late effects in general. Genome sequencing has laid the foundation for precision medicine, yet, clinical success remains moderate. Identifying therapeutic targets at the protein and pathway level by mass spectrometry-based proteomics holds great promise.
I will discuss analytical and systems challenges and propose possible strategies to smooth the path to full clinical translation. I will then present a proof of principle study in which we identified a possible treatment target in an adolescent with a recurrent rare malignancy. Within two weeks from biopsy, we conducted comprehensive DIA proteomics on H&E stained FFPE sections and validated a putative target by IHC. Following additional validation and failed chemotherapy and second line treatment the patient initiated a proteome guided monotherapy trial. I will then present an outlook how we envision to make pre-clinical proteome analysis and other innovative molecular pathology tests available to all children with cancer across Canada.